We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Cardinal Health (CAH - Free Report) closed at $215.13, marking a +1.11% move from the previous day. The stock's change was less than the S&P 500's daily gain of 2.51%. Meanwhile, the Dow experienced a rise of 2.85%, and the technology-dominated Nasdaq saw an increase of 2.8%.
The prescription drug distributor's stock has dropped by 1.97% in the past month, exceeding the Medical sector's loss of 5.12% and lagging the S&P 500's loss of 1.66%.
Market participants will be closely following the financial results of Cardinal Health in its upcoming release. The company plans to announce its earnings on April 30, 2026. The company's upcoming EPS is projected at $2.8, signifying a 19.15% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $62.42 billion, showing a 13.74% escalation compared to the year-ago quarter.
CAH's full-year Zacks Consensus Estimates are calling for earnings of $10.31 per share and revenue of $259.27 billion. These results would represent year-over-year changes of +25.12% and +16.48%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Cardinal Health. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Currently, Cardinal Health is carrying a Zacks Rank of #2 (Buy).
In terms of valuation, Cardinal Health is currently trading at a Forward P/E ratio of 20.63. This indicates a premium in contrast to its industry's Forward P/E of 15.09.
Meanwhile, CAH's PEG ratio is currently 1.37. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical - Dental Supplies industry stood at 1.74 at the close of the market yesterday.
The Medical - Dental Supplies industry is part of the Medical sector. With its current Zacks Industry Rank of 74, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Cardinal Health (CAH) Gains But Lags Market: What You Should Know
In the latest trading session, Cardinal Health (CAH - Free Report) closed at $215.13, marking a +1.11% move from the previous day. The stock's change was less than the S&P 500's daily gain of 2.51%. Meanwhile, the Dow experienced a rise of 2.85%, and the technology-dominated Nasdaq saw an increase of 2.8%.
The prescription drug distributor's stock has dropped by 1.97% in the past month, exceeding the Medical sector's loss of 5.12% and lagging the S&P 500's loss of 1.66%.
Market participants will be closely following the financial results of Cardinal Health in its upcoming release. The company plans to announce its earnings on April 30, 2026. The company's upcoming EPS is projected at $2.8, signifying a 19.15% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $62.42 billion, showing a 13.74% escalation compared to the year-ago quarter.
CAH's full-year Zacks Consensus Estimates are calling for earnings of $10.31 per share and revenue of $259.27 billion. These results would represent year-over-year changes of +25.12% and +16.48%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Cardinal Health. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Currently, Cardinal Health is carrying a Zacks Rank of #2 (Buy).
In terms of valuation, Cardinal Health is currently trading at a Forward P/E ratio of 20.63. This indicates a premium in contrast to its industry's Forward P/E of 15.09.
Meanwhile, CAH's PEG ratio is currently 1.37. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical - Dental Supplies industry stood at 1.74 at the close of the market yesterday.
The Medical - Dental Supplies industry is part of the Medical sector. With its current Zacks Industry Rank of 74, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.